ClinicalTrials.gg
Not yet recruitingNCT07857993Pix-MonitorUpdated Oct 5, 2026

DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response

An interventional study of DETECTRA and Standard of Care (SOC) in Rheumatic Disorder and Rheumatoid Arthritis (RA), sponsored by Centre Hospitalier Universitaire Vaudois. Not yet recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Centre Hospitalier Universitaire Vaudois · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 362 studies in Arthritis, Rheumatoid with a site in Germany — 27 open to participants now, 50 under way, 3 of them phase 3. Arthritis, Rheumatoid · Germany.

Planned enrollment
125th of 297
320 · median 259
Started
2026
with 6 others
No phase
19 of 362
4 open now
Primary completion
2028-12
later than 38 of 49 live
Registered
359th of 362
by date

Among the 362 studies in Arthritis, Rheumatoid with a site in Germany, this one is the 125th largest by planned enrollment of the 297 interventional ones that give a count, is one of 7 that started in 2026, is one of 19 with no phase, reaches primary completion later than 38 of the 49 other live ones, and was the 359th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

27 of the 362 studies in Arthritis, Rheumatoid with a site in Germany are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 362 studies in Arthritis, Rheumatoid with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the DETECTRA remote monitoring platform can help clinicians detect rheumatoid arthritis (RA) disease flares earlier and more reliably, as well as identify response and non-response or insufficient response to treatment, compared with standard care. The study will include patients with RA and will follow them for 12 months.

The main questions it aims to answer are:

In patients with remission or low disease activity (DAS28-CRP ≤ 2.6), does remote monitoring with patient-reported outcomes and self-performed imaging using DETECTRA enable earlier detection of disease flares compared with standard care? In patients with higher disease activity (DAS28-CRP > 2.6) who have switched medication, does DETECTRA enable earlier and more reliable identification of response and non-response or insufficient response to treatment compared with standard care?

Researchers will compare the DETECTRA intervention groups with standard-of-care control groups to see whether remote monitoring enables earlier and more reliable detection of changes in disease activity and treatment response.

Participants will:

Be assigned to a Low Disease Activity (LDA) or High Disease Activity (HDA) substudy based on their DAS28-CRP score at baseline.

Be randomly assigned within their substudy to either the DETECTRA remote monitoring group or the standard-of-care group.

In the DETECTRA group, regularly provide patient-reported outcomes and perform self-imaging of their hands remotely using the DETECTRA application.

Attend standard clinical assessments and be followed for 12 months.

03

Conditions studied

  • Rheumatic Disorder
  • Rheumatoid Arthritis (RA)

Keywords

  • rheumatoid arthritis
  • remote monitoring
  • flare detection
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years and ≤ 80 years
  • Diagnosed with RA according to the EULAR 2010 criteria
  • Affection of at least one hand joint in the past (synovitis, tenderness, dactylitis, tenosynovitis)
  • Must provide and sign the study's prior to any study-related procedures;
  • Able to understand and interact with the study team
  • Agree to comply in good faith with all conditions of the recordings, and to attend all required study procedures

Exclusion criteria

Exclusion Criteria:

  • Deformation of the hands or patients who have undergone joint arthrodesis or arthroplasty
  • Known microcrystal disease (e.g. gout, calcium pyrophosphate deposition) if hands are affected or pre-existing immune-mediated rheumatic diseases such as systemic lupus erythematosus or Sjögren's disease in the past 2 years
  • Lymphoedema in arms or hands following an axillary lymph node dissection
  • therapy for other conditions \<2 years ago
  • Immunosuppressive therapy for other autoimmune conditions with B-cell depletion \<5 years ago
  • Haematological or oncological treatments involving induction and / or maintenance chemotherapy \<5 years
  • Aged >80 years
  • Participation in another investigation with an drug or another MD within the 30 days preceding the trial or currently participating or planning to participate in an interventional trial
  • Inability to provide written
  • Severe cognitive impairment, severe psychiatric conditions or other inability to follow the procedures of the study
  • No regular access (weekly) to a smartphone
  • Adults who lack capacity to consent, known pregnant and breastfeeding women
  • Subjects for whom routine examination of the musculoskeletal system is not possible, or whose hands cannot be imaged (e.g., bandages that cannot be removed for hand picture taking, or injuries affecting the PIP joints both persisting for > 27 days)
  • Enrolment of the PI, his/her family members, employees and other dependent persons
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    DETECTRA low disease activity (LDA)

    Inclusion criteria for being randomized within the LDA study: • DAS28-CRP ≤ 2.6 Participants in this group will receive standard of care treatment and in addittion receive the DETECTRA application which they will use on a weekly basis during 12months.

    Device: DETECTRA

  • Experimental
    DETECTRA high disease activity (HDA)

    Inclusion criteria for being randomized withing the HDA study: * DAS28-CRP \> 2.6 * A change or start of any DMARDs treatment Participants in this arm will receive standard of care treatment and in addition will use the DETECTRA app on a weekly basis for 12months.

    Device: DETECTRA

  • Other
    Standard of Care - low disease activity

    Inclusion criteria for being randomized within the LDA study: • DAS28-CRP ≤ 2.6 Participants in this arm will receive the standard of care treatment.

    Other: Standard of Care (SOC)

  • Other
    Standard of Care - high disease activity

    Inclusion criteria for being randomized withing the HDA study: * DAS28-CRP \> 2.6 * A change or start of any DMARDs treatment Particiapnts in this arm will receive standard of care treatment.

    Other: Standard of Care (SOC)

Interventions

  • DeviceDETECTRA

    DETECTRA is a mobile application to be used on a weekly basis by patients where they submit hand images as well as report patient reported outcomes.

  • OtherStandard of Care (SOC)

    Standard of care for rheumatoid arthritis informed by EULAR guidelines.

06

What researchers measure

Primary outcomes

  1. Time to response to treatment detection

    HDA groups: •Time in (days) from study enrolment to response to treatment detection in RA (defined as DAS28 change of \> 0.6 between 2 visits / CDAI improvement ≥ 6 points to baseline at 3 months and current CDAI remaining ≤ 10 points) comparing the DETECTRA group to the standard care group.

    Time frame: From study enrollment to the end of study at 12months.

  2. Time to flare detection

    LDA groups: •Time (in days) from study enrolment to confirmed flare (defined as Change of Clinical Disease Activity Index (CDAI) ≥ 4.5 points from last visit \& current CDAI \> 10 or change of DAS28-CRP \> 1.2 and the current DAS28 ≥ 2.6) and

    Time frame: From enrollment to the end of study at 12months.

Secondary outcomes

  1. Diagnostic accuracy

    Diagnostic accuracy of the DETECTRA system to differentiate between presence and absence of a flare / non-response / insufficient response to treatment (as defined by clinical examination) will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

    Time frame: From study enrollment until end of study at 12months.

  2. Sensitivity

    Missed flares/non-response / insufficient response to treatment of clinical arthritis in the intervention group: This endpoint will be assessed if a patient comes for a visit based on his request and in any visit. Any confirmed flare is classified as a missed flare if a patients request a visit (or in a planned visits) without that the physician had previously recognized signs via the dashboard of a potential flare.

    Time frame: From study enrollment until end of study at 12months.

  3. Specificity

    False flares/detection of non-response / insufficient response to treatment in the intervention group will be assessed at any interim visit and is reported if a patient got flagged via the dashboard, came in for confirmation but does not get confirmation of a flare or of a non-response / insufficient response to treatment.

    Time frame: From enrollment until end of study at 12months.

  4. Adherence

    Percentage of submissions on the application (totally expected submissions = every week until end of trial) for patients in the DETECTRA intervention group.

    Time frame: From enrollment until the end of study at 12months.

  5. Adherence

    Average amount of reminders (calls by the study nurse but not the automatic reminders via the app) per patient needed during the duration of the study (1year). For participants in the DETECTRA arms.

    Time frame: From enrollment until the end of study at 12months.

  6. Cost-effectiveness estimates

    The primary outcome of interest for the health economic evaluation is cost-effectiveness, expressed as the incremental cost per Quality-Adjusted Life Year (QALY) gained through the use of DETECTRA compared to standard of care. Data for the evaluation will be collected from both the DETECTRA system and clinical records during the trial. Through the app, patients will report PROs including self-assessed joint counts (tender and swollen), global pain and stiffness scores (via VAS-like scales), medication use, free-text symptom notes, and joint-specific pain reports. At the clinic level, data will be collected on the timing and number of visits, formal RA diagnoses, and DMARD treatment initiations and changes. These trial-derived endpoints, particularly time-to-flare detection and amount of visits, will inform a Markov model to extrapolate long-term costs and outcomes beyond the trial period.

    Time frame: From enrollment until end of study at 12months.

  7. Number of consultations

    LDA group only: Difference in number of consultations within the 12months study period in the DETECTRA group as compared to the standard group.

    Time frame: From enrollment until the end of study at 12months.

  8. Difference in DAS28-CRP

    After 12 months will be assessed by a trained rheumatologist in the DETECTRA group as compared to the standard group.

    Time frame: From enrollement until the end of study at 12months.

  9. Difference in Simplified Disease Activity Index (SDAI)

    Difference in SDAI after 12 months will be assessed by a trained rheumatologist in the DETECTRA group as compared to the standard group.

    Time frame: From enrollment until end of study at 12months.

  10. Remission rates

    Percentage of patients in remission after 12 months, will be assessed by a trained rheumatologist in the DETECTRA group as compared to the standard group.

    Time frame: From enrollment until the end of study at 12months.

  11. Sensitivity to change

    Sensitivity to change will be calculated for the biomarker (FFI) using the Standardized Response Mean (SRM), defined as the mean change from baseline to follow-up divided by the standard deviation of the change scores.

    Time frame: From enrollment until the end of study at 12months.

  12. Patient empowerment

    Regular self-reporting and feedback may increase perceived empowerment, trust in care, and shared decision-making (to be measured via PGIC).

    Time frame: From enrollment until the end of study at 12months.

  13. Mental health & Quality of Life:

    For diagnosed patients, reassurance from remote monitoring and reduced flare anxiety may improve mental health (measured via SF-36).

    Time frame: From enrollment until the end of study at 12months.

  14. Usability and acceptance

    This will be measured with the System Usability Scale (SUS) at the end of the trial within patients and HCPs who were using the app or the dashboard during the trial.

    Time frame: From enrollment until the end of study at 12months.

Other outcomes

  1. Exploratory validation of additional imaging-derived metrics (e.g., finger joint geometry, patterns, motility)

    Images and videos from any time-point of the investigation taken via the DETECTRA system will be used to support future enhancements of DETECTRA and the algorithms of the system.

    Time frame: From enrollment until the end of study at 12months.

  2. Diagnostic accuracy FFI

    Diagnostic accuracy of the FFI to differentiate between presence and absence of synovitis (as defined by clinical examination and or ultrasound) will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

    Time frame: From enrollment until the end of study at 12months.

  3. Thermal imaging dataset construction

    • Data completeness: The number of valid thermal images successfully linked with their corresponding comprehensive set of clinical, demographic, laboratory, and ultrasound reference data.

    Time frame: From enrollment until the end of study at 12months.

  4. Thermal imaging

    Data quality: Assessment of image technical quality (e.g., image noise, hand position, absence of artifacts) to ensure suitability for future image processing.

    Time frame: From enrollment until the end of study at 12months.

  5. Thermal imaging

    Dataset integrity: The successful compilation of a structured dataset suitable for the development and validation of artificial intelligence models

    Time frame: From enrollment until the end of study at 12months.

07

Study locations

3 sites
08

References and documents

Publications

  • Frederiksen BA, Hammer HB, Terslev L, Ammitzboll-Danielsen M, Savarimuthu TR, Weber ABH, Just SA. Automated ultrasound system ARTHUR V.2.0 with AI analysis DIANA V.2.0 matches expert rheumatologist in hand joint assessment of rheumatoid arthritis patients. RMD Open. 2025 Aug 5;11(3):e005805. doi: 10.1136/rmdopen-2025-005805. PubMed 40764087 ↗
  • Konzett V, Kerschbaumer A, Smolen JS, Kristianslund EK, Provan SA, Kvien TK, Aletaha D. Definition of rheumatoid arthritis flare based on SDAI and CDAI. Ann Rheum Dis. 2024 Jan 11;83(2):169-176. doi: 10.1136/ard-2023-224742. PubMed 37890977 ↗
  • Morales-Ivorra I, Narvaez J, Gomez-Vaquero C, Moragues C, Nolla JM, Narvaez JA, Marin-Lopez MA. Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique. RMD Open. 2022 Jul;8(2):e002458. doi: 10.1136/rmdopen-2022-002458. PubMed 35840312 ↗
  • Koller C, Maglione J, Blanchard M, Kleyer A, Folle L, Geurts J, Hugle T. Clinical investigation of a digital biomarker for joint swelling in inflammatory arthritis based on automated quantification of dorsal finger fold patterns. Sci Rep. 2026 Jun 6;16(1):24727. doi: 10.1038/s41598-026-56797-8. PubMed 42249051 ↗
  • Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006 Dec 15;55(6):864-72. doi: 10.1002/art.22353. PubMed 17139662 ↗
  • Raza K, Stack R, Kumar K, Filer A, Detert J, Bastian H, Burmester GR, Sidiropoulos P, Kteniadaki E, Repa A, Saxne T, Turesson C, Mann H, Vencovsky J, Catrina A, Chatzidionysiou A, Hensvold A, Rantapaa-Dahlqvist S, Binder A, Machold K, Kwiatkowska B, Ciurea A, Tamborrini G, Kyburz D, Buckley CD. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis. 2011 Oct;70(10):1822-5. doi: 10.1136/ard.2011.151902. Epub 2011 Aug 7. PubMed 21821867 ↗
  • Rosa JE, Garcia MV, Luissi A, Pierini F, Sabelli M, Mollerach F, Soriano ER. Rheumatoid Arthritis Patient's Journey: Delay in Diagnosis and Treatment. J Clin Rheumatol. 2020 Oct;26(7S Suppl 2):S148-S152. doi: 10.1097/RHU.0000000000001196. PubMed 31609811 ↗
  • Kernder A, Thiele K, Chehab G, Schneider M, Callhoff J. Time interval between the onset of connective tissue disease symptoms and first contact with a rheumatologist: results from the German National Database of collaborative arthritis centers. Rheumatol Int. 2023 Aug;43(8):1453-1458. doi: 10.1007/s00296-023-05335-0. Epub 2023 Jun 1. PubMed 37258745 ↗
  • Mucke J, Knitza J, Muehlensiepen F, Grahammer M, Stenzel R, Simon D, Kleyer A, Kronke G, Sharp C, Bendzuck G, Korinth M, Elling-Audersch C, Vuillerme N, Schett G, Pecher AC, Krusche M. TELERA-Asynchronous TELEmedicine for Patients With Rheumatoid Arthritis: Study Protocol for a Prospective, Multi-Center, Randomized Controlled Trial. Front Med (Lausanne). 2021 Dec 13;8:791715. doi: 10.3389/fmed.2021.791715. eCollection 2021. PubMed 34966765 ↗
  • Myasoedova E, De Thurah A, Erpelding ML, Schneeberger EE, Maribo T, Citera G, Davis JM, Matteson EL, Crowson CS, Fautrel B, Guillemin F. Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire. Semin Arthritis Rheum. 2020 Apr;50(2):261-265. doi: 10.1016/j.semarthrit.2019.09.004. Epub 2019 Sep 11. PubMed 31526593 ↗
  • Bernard L, Valsecchi V, Mura T, Aouinti S, Padern G, Ferreira R, Pastor J, Jorgensen C, Mercier G, Pers YM. Management of patients with rheumatoid arthritis by telemedicine: connected monitoring. A randomized controlled trial. Joint Bone Spine. 2022 Oct;89(5):105368. doi: 10.1016/j.jbspin.2022.105368. Epub 2022 Mar 4. PubMed 35248737 ↗
  • Venerito V, Manigold T, Capodiferro M, Markham D, Blanchard M, Iannone F, Hugle T. Single-camera motion capture of finger joint mobility as a digital biomarker for disease activity in rheumatoid arthritis. Rheumatol Adv Pract. 2025 Apr 18;9(2):rkae143. doi: 10.1093/rap/rkae143. eCollection 2025. PubMed 40256629 ↗
  • Hugle T, Caratsch L, Caorsi M, Maglione J, Dan D, Dumusc A, Blanchard M, Kalweit G, Kalweit M. Dorsal Finger Fold Recognition by Convolutional Neural Networks for the Detection and Monitoring of Joint Swelling in Patients with Rheumatoid Arthritis. Digit Biomark. 2022 Jun 8;6(2):31-35. doi: 10.1159/000525061. eCollection 2022 May-Aug. PubMed 35949225 ↗
  • Takase-Minegishi K, Horita N, Kobayashi K, Yoshimi R, Kirino Y, Ohno S, Kaneko T, Nakajima H, Wakefield RJ, Emery P. Diagnostic test accuracy of ultrasound for synovitis in rheumatoid arthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2018 Jan 1;57(1):49-58. doi: 10.1093/rheumatology/kex036. PubMed 28340066 ↗
  • Lavezzari G, Womack AW. Industry perspectives on biomarker qualification. Clin Pharmacol Ther. 2016 Feb;99(2):208-13. doi: 10.1002/cpt.264. Epub 2015 Oct 22. PubMed 26378777 ↗
  • Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, Veale DJ. The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis. Front Med (Lausanne). 2018 Aug 3;5:185. doi: 10.3389/fmed.2018.00185. eCollection 2018. PubMed 30123796 ↗
  • Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017 Jul;29(4):323-330. doi: 10.1097/BOR.0000000000000389. PubMed 28422773 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 25 months is close to that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 5, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857993
Collaborators
Staatssekretariat für Bildung Forschung und Innovation SBFI, Horizon 2020 - European Commission
Responsible party
Thomas Hügle (Prof. Dr. Thomas Hügle - Head of departement, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Oct 5, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Thomas Hügle, Prof.
Contact
thomas.hugle@chuv.ch
+41795568068
Thomas hügle, Prof.
principal investigator · Centre hospitalier universitaire vaudois (CHUV)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion